Survival Benefit for Induction Chemo in Nasopharyngeal Carcinoma

The majority of patients diagnosed with nasopharyngeal carcinoma are at an advanced stage and have a poor prognosis. Concurrent platinum-based chemotherapy and radiation is currently the standard of care for these patients with high risk, but this treatment is associated with a high rate of relapse. In phase II trials, induction chemotherapy with gemcitabine and […]

Read More

Breast Cancer Risk Increased by Menopausal Hormonal Therapy

Menopausal hormonal therapy (MHT), used to alleviate the symptoms of menopause, has been associated with an increased risk of breast cancer; but findings from previous studies have been inconsistent and lack long-term follow-up. A large, new meta-analysis of published and unpublished sources evaluated 108,647 postmenopausal women, who developed breast cancer, for history of MHT use […]

Read More

ctDNA as a Biomarker of Recurrence and Prognosis in Early-Stage CRC

Adjuvant chemotherapy is standard of care for stage III colorectal cancer (CRC) and high-risk stage II CRC. However, decision making for adjuvant therapy is imperfect and based on risk stratification by stage and clinical risk factors. In recent years, circulating tumor DNA (ctDNA) has emerged as a promising noninvasive and dynamic biomarker for monitoring genomic […]

Read More

Role of Alpelisib in HR-Positive PIK3CA-Mutated Advanced Breast Cancer

The standard of care for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast is endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor. Despite improvements in patient outcomes, a majority of patients eventually develop acquired resistance to endocrine-based therapy that is challenging to treat. […]

Read More

TMB Predicts Efficacy of Immune Checkpoint Inhibitors in MSI-H mCRC

Microsatellite instability (MSI) is a recognized biomarker of response to immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC). However, not all MSI-H patients respond to ICIs, indicating a need for additional biomarkers. In many cancers, tumor mutation burden (TMB) has been shown to be associated with response to immunotherapy, regardless of MSI status or […]

Read More

Presence of Oral HPV After Treatment of HNSCC May Predict Recurrence

An increasing number of patients with oropharyngeal head and neck squamous cell carcinoma (HNSCC) have human papillomavirus (HPV) associated cancer. Although HPV-positive oropharyngeal cancers are generally less aggressive than HPV-negative tumors, around 20% of HPV-positive patients experience cancer progression and death within 5 years. Thus, markers to identify patients at risk for recurrence are needed. […]

Read More

Consensus Molecular Subtypes Predict Outcomes in Patients With mCRC

Adoption of personalized treatment approaches in metastatic colorectal cancer (mCRC), which takes into consideration factors such as primary tumor location, RAS mutation status, and presence of microsatellite instabilities (MSI) for treatment selection, combined with an increased number of treatment options, has led to significant improvements in survival. However, the prognosis of patients with mCRC generally […]

Read More

Single-Fraction SBRT Standard of Care for Painful Bone Metastases

Bone is a common metastatic site of advanced cancer. Durable pain control is a major goal of palliative care and important for maintaining quality of life cancer patients. Radiotherapy is the primary method for palliation of painful bone metastases, but there is no consensus regarding optimal dose and fractionation. Although no differences in pain relief […]

Read More

Interesting Articles Worth Reading

New Multiple Myeloma Treatment Guidelines. In recent years, several novel agents from across multiple lines of therapy have emerged for management of multiple myeloma. To aid physicians in evaluating new data and selecting the best treatment from a variety of options, the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario released updated treatment […]

Read More